Orchard Therapeutics Limited

Pfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these

With a growing number of complex cell and gene therapies approved globally, mostly for rare disease populations, manufacturers are looking at how to make these products more accessible by delivering a

The overall flow of funding into the biopharmaceutical industry is increasing in 2024 relative to 2022 and 2023, but investors continue to see risk in the drug development sector, placing their bets o

A string of complete response letters from the US FDA clouded the 2024 outlook for novel cancer therapies, but a productive pipeline is carrying enough candidates towards second half user fee goal dat